MOLECULAR TEST MANAGEMENT FOR GREATER LAB CONNECTIVITY
How can labs extend their value at the point of care, deliver a better experience for oncologists and align with payer preferences?
Trapelo is the first, evidence-based technology platform that gives lab managers and pathologists closer connectivity with ordering physicians and payers to reduce friction, optimize the flow of molecular testing, improve order accuracy and maintain lab volume.
In addition to lab order decision support, Trapelo’s Actionable Results Viewer presents lab results in an easy-to-evaluate format that ranks treatment options according to the latest published clinical evidence and review by our own scientific team, which further ranks treatments by the level of evidence. The platform also highlights those treatments that may be automatically authorized for reimbursement.
Trapelo is lab agnostic and welcomes the opportunity to work with all labs. We currently facilitate orders to some of the nation’s largest labs.
Trapelo's Pathology Comment Module supports lab annotations to help physicians better understand report results and make more informed treatment decisions.
"In addition to offering an innovative and cost-effective way to choose the right test for the right patient in advance, Trapelo's comprehensive, point-of-care clinical reporting protects patients from prematurely translated genomic findings."
– Michelle, Afkhami, City of Hope, Medical Director, Clinical Molecular Diagnostic Lab
Trapelo for Pathologists is:
Provides oncology teams with evidence-based guidance on what to order and for which patients, and then maps the recommended tests to biomarker panels to minimize order mistakes, save time and tissue, and expedite the order process
Ensures patients get the most appropriate tests through the proper molecular testing pathway at the right time in their treatment journey. Trapelo also helps drive clinical trial accruals which is critical to expanding patient care.
Automates the test ordering process through an institution's central lab, ensuring that all oncologists in the practice are utilizing internal expertise and capabilities. This minimizes outsourcing and enables pathology departments to maintain or grow lab volume.
Provides unmatched transparency between payers and labs to streamline and optimize prior authorization and reimbursement programs
Some of the nation’s leading cancer centers and community oncologists, along with national and regional molecular testing labs, have endorsed Trapelo’s innovative approach to ensuring the scalable, appropriate use of precision medicine for cancer.
How can we resolve the complexities of using precision medicine for cancer care?
Some experts have suggested the role of pathologists will diminish as precision medicine evolves but Dr. Tony Magliocco, Chair of the Department of Pathology at the H. Lee Mofftt Cancer Center, believes that as the go-to genomic experts, pathologists are uniquely positioned to move the field forward. Listen to the premiere episode of The Precision Medicine Podcast here.